WuXi Biologics opened MFG18, its first GMP phase I drug substance clinical production facility, in Cranbury, New Jersey, USA.
With solely single-use technology, the 154,448 square foot site's operational capacity for clinical manufacture will increase to 6,000 litres from its initial capacity of 4,000 litres.
The plant, which was built in response to the expanding demand of customers around the world, is WuXi Bio's first GMP manufacturing facility in North America.
The site plays a crucial role in WuXi Biologics' global dual sourcing strategy, which makes it possible for products to be produced and materials to be sourced at various WuXi Biologics locations across the globe.
When fully operational, the facility will have over 250 personnel, up from over 150 at the moment.